Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation

Pharmacoepidemiology and Drug Safety

Volumn 23, Issue 12, 2014, Pages 1238-1246

  Sessler, Nelson E ^a   Downing, Jerod M ^a   Kale, Hrishikesh ^a   Chilcoat, Howard D ^a,c   Baumgartner, Todd F ^a   Coplan, Paul M ^a,b  

^a PURDUE PHARMA L P   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Abuse deterrent; Extended release oxycodone; Overdose death; OxyContin; Pharmacoepidemiology; Pharmacovigilance

Indexed keywords

OXYCODONE; DELAYED RELEASE FORMULATION; DRUG DOSAGE FORM;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED RELEASE FORMULATION; DRUG ABUSE; DRUG FATALITY; DRUG OVERDOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EXTENDED RELEASE FORMULATION; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OPIATE ADDICTION; PRIORITY JOURNAL; RISK MANAGEMENT; CHEMISTRY; CHILD; DATA BASE; DELAYED RELEASE FORMULATION; DRUG DOSAGE FORM; MEDICINAL CHEMISTRY; MIDDLE AGED; MORTALITY; STANDARDS; TRENDS; UNITED STATES;

ADOLESCENT; ADULT; AGED; CHEMISTRY, PHARMACEUTICAL; CHILD; DATABASE MANAGEMENT SYSTEMS; DELAYED-ACTION PREPARATIONS; DOSAGE FORMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; OXYCODONE; UNITED STATES;

EID: 84914144189     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3658     Document Type: Article

References (56)

1. American Academy of Pain Medicine. Use of Opioids for the Treatment of Chronic Pain. American Academy of Pain Medicine: Chicago, IL, 2013.
2. American Geriatrics Society Panel on Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc 2009; 57: 1331-1346. doi. 10.1111/j.1532-5415.2009.02376.x.
3. Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10: 113-130. doi:10.1016/j.jpain.2008.10.008.
4. Management of Opioid Therapy for Chronic Pain Working Group. VA/DoD clinical practice guideline for management of opioid therapy for chronic pain. Department of Veterans Affairs, Department of Defense: Washington, DC, 2010.
5. National Opioid Use Guideline Group. Canadian guideline for safe and effective use of opioids for chronic non-cancer pain. Part B: recommendations for practice. National Opioid Use Guideline Group (NOUGG): Hamilton, Canada, 2010.
6. Jones CM, Mack KA, Paulozzi LJ. Pharmaceutical overdose deaths, United States, 2010. JAMA 2013; 309: 657-659. doi:10.1001/jama.2013.272.
7. Okie S. A flood of opioids, a rising tide of deaths. N Engl J Med 2010; 363: 1981-1983. doi:10.1056/NEJMp1011512.
8. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005; 11: 469-479.
9. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006; 22: 667-676.
10. Raffa RB, Pergolizzi JV. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70: 1657-1675. doi:10.2165/11537940-000000000-00000.
11. Katz N, Dart RC, Bailey E, et al. Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse 2011; 37: 205-217. doi:10.3109/00952990.2011.569623.
12. National Drug Intelligence Center. OxyContin diversion and abuse. January 2001. http://www.justice.gov/archive/ndic/pubs/651/abuse.htm [23 February 2012].
13. Hays L, Kirsh KL, Passik SD. Seeking drug treatment for OxyContin abuse: a chart review of consecutive admissions to a substance abuse treatment facility in Kentucky. J Natl Compr Canc Netw 2003; 1: 423-428.
14. Hays LR. A profile of OxyContin addiction. J Addict Dis 2004; 23: 1-9.
15. Butler SF, Black RA, Grimes Serrano JM, et al. Characteristics of prescription opioid abusers in treatment: prescription opioid use history, age, use patterns and functional severity. J Opioid Manag 2010; 6: 239-252.
16. Romach MB, Schoedel KA, Seller EM. Update on tamper-resistant drug formulations. Drug Alcohol Depend 2013; 130: 13-23. doi:10.1016/j.drugalcdep.2012.12.028.
17. Moorman-Li R, Motycka CA, Inge LD, et al. A review of abuse-deterrent opioids for chronic nonmalignant pain. PT 2012; 37: 412-418.
18. OxyContin [full prescribing information]. Stamford, CT: Purdue Pharma L.P. 7/2013.
19. Centers for Disease Control and Prevention. CDC grand rounds: prescription drug overdoses-a U.S. Epidemic. Morb Mortal Wkly Rep 2012; 61: 10-13.
20. Cone EJ, Fant RV, Rohay JM, et al. Oxycodone involvement in drug abuse deaths: a DAWN-based classification scheme applied to an oxycodone postmortem database containing over 1000 cases. J Anal Toxicol 2003; 27: 57-67; discussion 67.
21. Dhalla IA, Mamdani MM, Sivilotti ML, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181: 891-896. doi:10.1503/cmaj.090784.
22. Butler SF, Black RA, Cassidy TA, et al. Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J 2011; 8: 29-45. doi:10.1186/1477-7517-8-29.
23. Butler SF, Budman SH, Licari A, et al. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf 2008; 17: 1142-1154. doi:10.1002/pds.1659.
24. Katz N, Fernandez K, Chang A, et al. Internet-based survey of nonmedical prescription opioid use in the United States. Clin J Pain 2008; 24: 528-535. doi:10.1097/AJP.0b013e318167a087.
25. Passik SD, Hays L, Eisner N, et al. Psychiatric and pain characteristics of prescription drug abusers entering drug rehabilitation. J Pain Palliat Care Pharmacother 2006; 20: 5-13.
26. Cone EJ, Giordano J, Weingarten B. An iterative model for in vitro laboratory assessment of tamper deterrent formulations. Drug Alcohol Depend 2013; 131: 100-105. doi:10.1016/j.drugalcdep.2012.12.006.
27. Sellers EM, Perrino PJ, Colucci SV, Harris SC. Attractiveness of reformulated OxyContin(R) tablets: assessing comparative preferences and tampering potential. J Psychopharmacol 2013; 27(9): 808-816. doi: 10.1177/0269881113493364.
28. ® tablets in healthy adults. Clin Drug Investig 2013; 33: 441-449. doi:10.1007/s40261-013-0085-x.
29. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367: 187-189. doi:10.1056/NEJMc1204141.
30. Butler SF, Cassidy TA, Chilcoat H, et al. Abuse rates and routes of administration of reformulated extended-release oxycodone: initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain 2013; 14: 351-358. doi:10.1016/j.jpain.2012.08.008.
31. ® in 2010. J Pain 2013; 14: 1122-1130. doi:10.1016/j.jpain.2013.04.011.
32. Coplan PM, Kale H, Sandstrom L, et al. Changes in oxycodone and heroin exposures in the national poison data system after introduction of extended-release oxycodone with abuse deterrent characteristics. Pharmacoepidemiol Drug Saf 2013; 22: 1274-1282. doi:10.1002/pds.3522.
33. Food and Drug and Administration. 2013b. FDA news release: FDA approves abuse-deterrent labeling for reformulated OxyContin, Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ UCM348252.htm [5 May 2013].
34. Kessler DA. Introducing MEDWatch. A new approach to reporting medication and device adverse effects and product problems. JAMA 1993; 269: 2765-2768.
35. U.S. Food and Drug and Administration (FDA). Adverse event reporting system (AERS).Rockville, MD: FDA. Available from: http://www.fda.gov/cder/aers/default.htm [28 January 2013].
36. Greenland S. Dose response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology 1995; 6: 356-365.
37. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology (3rd edn). Lippincott, Williams & Wilkins: Philadelphia, PA, 2008; 410.
38. IMS health national prescription audit data purchased and received December 2013
39. Ahmad SR. Adverse drug event monitoring at the Food and Drug Administration. J Gen Intern Med 2003; 18: 57-60.
40. Gibbons RD, Amatya AK, Brown CH, et al. Post-approval drug safety surveillance. Annu Rev Public Health 2010; 31: 419-437. doi:10.1146/annurev.publhealth.012809.103649.
41. Rodriguez EM, Staffa A, Graham D. The role of databases in drug post-marketing surveillance. Pharmacoepidemiol Drug Saf 2001; 10: 407-410. doi:10.1002/pds.615.
42. Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, Coplan PM, Chilcoat HD. The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend [available ahead of print 27 February 2014] doi: 10.1016/j.drugalcdep.2014.02.018.
43. Florida medical examiners commission report for 2012. Available at: http://www.fdle.state.fl.us/Content/getdoc/79241c67-253b-45eb-a238-1a07cf4a2a0c/2012-Drug-Report_Final.aspx [1 October 2013].
44. Badalamenti VC, Buckley JW, Smith ET. Safety of EMBEDA (morphine sulfate and naltrexone hydrochloride) extended-release capsules: review of post-marketing adverse events during the first year. J Opioid Manag 2012; 8: 115-125.
45. Pearl J. Causality: Models, Reasoning and Inference. Cambridge University Press: Cambridge, United Kingdom, 2009; 5.
46. FDA News Release. FDA introduces new safety measures for extended-release and long-acting opioid medications. July 9, 2012. Available at: http://www.fda.gov/ NewsEvents/ Newsroom/PressAnnouncements/ucm310870.htm [30 March 2013].
47. U.S. Department of Justice Drug Enforcement Administration. Prescription drug monitoring programs. Available at: http://www.deadiversion.usdoj.gov/faq/rx_monitor.htm [January 2011].
48. Reifler LM, Droz D, Bailey JE, et al. Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Med 2012; 13: 434-442. doi:10.1111/j.1526-4637.2012.01327.x.
49. Paulozzi LJ, Kilbourne EM, Desai HA. Prescription drug monitoring programs and death rates from drug overdose. Pain Med 2011; 12: 747-754. doi:10.1111/j.1526-4637.2011.01062.x.
50. Sauber-Schatz EK, Mack KA, Diekman ST, et al. Associations between pain clinic density and distributions of opioid pain relievers, drug-related deaths, hospitalizations, emergency department visits, and neonatal abstinence syndrome in Florida. Drug Alcohol Depend 2013; 133: 161-166. doi:10.1016/j.drugalcdep.2013.05.017.
51. Albert S, Brason FW, Sanford CK, et al. Project Lazarus community-based overdose prevention in rural North Carolina. Pain Med 2011; 12(Suppl 2): S77-S85. doi:10.1111/j.1526-4637.2011.01128.x.
52. Centers for Disease Control and Prevention. Community-based opioid overdose prevention programs providing naloxone-United States, 2010. MMWR Morb Mortal Wkl Rep 2012; 61: 101-105.
53. National take-back initiative. US Department of Justice, Drug Enforcement Administration, Office of Diversion Control Web site. http://www.deadiversion.usdoj.gov/drug_disposal/takeback/ [11 February 2014].
54. Gray JA. Prescription drug abuse and DEA-sanctioned drug take-back events: characteristics and outcomes in rural Appalachia. Arch Intern Med 2012; 172: 1186-1187. doi:10.1001/archinternmed.2012.2374.
55. Silverman G. Heroin abuse: shooting up. Financial Times, February 9, 2014. Available at http://www.ft.com/intl/cms/s/0/d378673a-8fe3-11e3-aee9-00144feab7de.html?siteedition=intl.
56. Office of National Control Policy. Epidemic: responding to America's prescription drug abuse crisis, 2011. http://www.whitehouse.gov/ondcp/prescription-drug-abuse [30 March 2013].